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Abstract
Introduction: Intrinsic plasticity of breast carcinoma cells allows them to undergo a transient and reversible
conversion into mesenchymal cells to disseminate into distant organs, where they can re-differentiate to an
epithelial-like status to form a cohesive secondary mass. The p130Cas scaffold protein is overexpressed in human
ER+ and HER2+ breast cancer where it contributes to cancer progression, invasion and resistance to therapy.
However, its role in regulating mesenchymal aggressive breast cancer cells remains to be determined. The aim of
this study was to investigate the molecular and functional involvement of this adaptor protein in breast cancer cell
plasticity.
Methods: We used silencing strategies and rescue experiments to evaluate phenotypic and biochemical changes
from mesenchymal to epithelial traits in breast tumor cell lines. In the mouse A17 cell model previously related to
mesenchymal cancer stem cells and basal-like breast cancer, we biochemically dissected the signaling pathways
involved and performed functional in vivo tumor growth ability assays. The significance of the signaling platform
was assessed in a human setting through the use of specific inhibitors in aggressive MDA-MB-231 subpopulation
LM2-4175 cells. To evaluate the clinical relevance of the results, we analyzed publicly available microarray data from
the Netherlands Cancer Institute and from the Koo Foundation Sun Yat-Sen Cancer Center.
Results: We show that p130Cas silencing induces loss of mesenchymal features, by downregulating Vimentin,
Snail, Slug and Twist transcriptional factors, resulting in the acquirement of epithelial-like traits. Mechanistically,
p130Cas controls Cyclooxygenase-2 transcriptional expression, which in turn contributes to p130Cas-dependent
maintenance of mesenchymal phenotype. This cascade of events also compromises in vivo tumor growth through
inhibition of cell signaling controlling cell cycle progression. c-Src and JNK kinases are sequential players in
p130Cas/ Cyclooxygenase-2 axis and their pharmacological inhibition is sufficient to downregulate Cyclooxygenase-
2 leading to an epithelial phenotype. Finally, in silico microarray data analysis indicates that p130Cas and
Cyclooxygenase-2 concomitant overexpression predicts poor survival and high probability of breast tumor
recurrence.
Conclusions: Overall, these data identify a new p130Cas/Cyclooxygenase-2 axis as a crucial element in the control
of breast tumor plasticity, opening new therapeutic strategies leading to inhibition of these pathways in aggressive
breast carcinoma.
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Introduction
p130Cas is a tyrosine phosphorylated scaffold molecule
originally identified in cells transformed by v-c-Src and
v-Crk oncogenes [1-3]. p130Cas structural motifs and its
posttranslational modifications enable interactions with
many proteins leading to multi-protein complexes that in
normal cells modulate cell motility, survival and prolif-
eration [3]. In addition, p130Cas acts as a primary force
sensor, transducing force into mechanical extension [4].
Extensive work on cancer cell models show that
p130Cas is involved in cancer initiation, progression and
metastasis formation [3]. p130Cas is necessary for trans-
formation by several oncogenes, such as c-Src [5] and
Her2 [6,7] as well as the oncogenic fusion protein nucleo-
phosmin (NPM1)-anaplastic lymphoma receptor tyrosine
kinase (ALK) [8]. Recently, p130Cas has been shown to be
required for K-Ras, b-Raf, PTEN and PIK3CA oncogene-
dependent proliferation [9]. Moreover, we have demon-
strated that p130Cas is required for driving invasion and
metastasis formation of HER2-transformed cells [10].
Finally, overexpression of p130Cas contributes to the
development of human breast cancer [3]. It has been
recently reported that in breast tumors overexpression of
both Her2 and p130Cas is associated with increased prolif-
eration, metastasis and poor prognosis [10,11]. Moreover,
high levels of p130Cas have also been associated with
resistance to the cytotoxic agent doxorubicin [12] and to
anti-estrogen receptor (ER) therapy [13,14].
During metastasis dissemination, epithelial cancer cells
can undergo a transient and reversible conversion into
individual, motile and invasive mesenchymal cells to
detach from the primary tumor, to disseminate into dis-
tant organs, and to form a cohesive secondary mass at a
metastatic site, where they can re-differentiate to an
epithelial-like status [15-19]. These processes, collectively
defined as epithelial-mesenchymal (EMT) and mesenchy-
mal-epithelia transition (MET), respectively, have been
shown to be driven by coding and noncoding genes [20];
however, the regulatory program that controls tumor cell
plasticity is not completely understood.
We previously established a carcinoma-derived
mesenchymal tumor cell line, called A17, from a mam-
mary carcinoma spontaneously developed in Balb-NeuT
transgenic mice. These cells express cytokeratin 14 sug-
gesting a myoepithelial origin, but not E-cadherin,
indicating a partial transdifferentiation toward a
mesenchymal phenotype [21]. The mesenchymal pheno-
type of A17 cells has been related to mesenchymal can-
cer stem cells and basal-like breast cancer [22,23].
Moreover, these cells significantly overexpress Cyclooxy-
genase-2 (Cox-2), a mesenchymal hallmark in tumors,
whose relevance in growth, vasculogenesis and invasive-
ness has been widely documented in various types of
carcinoma, both in clinical and experimental studies
[24]. A human model of mesenchymal basal-like breast
cancer is represented by the human lung metastatic
MDA-MB-231 subpopulation LM2-4175 cells [25,26].
These cells also overexpress Cox-2 [25]. Here, we show
that in these cells p130Cas silencing is sufficient to
induce a switch from mesenchymal to epithelial features,
to downregulate Cox-2 expression and mesenchymal
markers and to impair in vivo tumor growth properties.
Finally, we demonstrate that the concomitant expression
of p130Cas and Cox-2 correlates with poor prognosis of
human breast tumors. Taken together, these data
describe a new role of p130Cas in EMT and cancer pro-
gression through the regulation of Cox-2 expression.
Materials and methods
Antibody and reagents
p130Cas mAbs have been previously described [6].
mAbs to Vinculin were from Millipore (Billerica, MA,
USA). Abs to c-Src, p-Tyr PY99, Cyclin D1, Snail, Slug,
Twist and Actin were from Santa Cruz Biotechnologies
(Palo Alto, CA, USA). pTyr416 c-Src and pJnk (Thr183/
Tyr185) Abs were from Cell Signaling (Beverly, MA,
USA) and Abs to Cox-2 from Cayman Chemical (Ann
Arbor, MI, USA). Secondary antibodies conjugated with
peroxidase were from Sigma-Aldrich (St. Louis, MO,
USA). Collagen I was from BD Trasduction Laboratories
(Franklin Lakes, NY, USA). Doxycycline was purchased
from Sigma-Aldrich.
Cell cultures
A17 cells were cultured in DMEM-20% FCS and LM2-
4175 in DMEM-10% FCS. Doxycycline at a concentra-
tion of 1 microgram/ml was directly added to medium
and medium was changed every two to three days. The
specific inhibitors of c-Src (SU6656) or JNK (SP600125)
were used at a final concentration of 10 micromolar and
40 micromolar respectively for 16 hrs. Live images at
10X, 20X, magnification were collected with a Zeiss
microscopy (Oberkochen, Germany).
Generation of lentiviruses
Viral particles of pLVTHM carrying shRNA sequences
(Ctr shRNA, p130Cas shRNA, or Cox-2 shRNA) were
produced as described in [6]. For Cox-2 downregulation
the sequences used were: GCTGTTCCAATCCATGT-
CAAA (COX-2 shRNA) and TCTCGCTTGGGCGA-
GAGTAAGCTC (Ctr shRNA).
For p130Cas and Cox-2 expression, human p130Cas
cDNA, mouse p130Cas cDNA fused with GFP or human
Cox-2 cDNA, respectively, were cloned into pCCL lenti-
viral vector, and viral particles production was performed
as described above.
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For silencing p130Cas in LM2-4175 cells, the human
shRNA sequence (5’CCTTGCAGTACCCATCGCCTT3’)
was inserted into pLKO vector purchased from Open
Biosystems (Thermo Fisher Scientific, Waltham, MA,
USA). Lentiviruses were produced according to manu-
facturer’s instructions.
RNA isolation and qRT-PCR for mRNA detection
Total RNA was isolated from cells using TRIzol™ Reagent
(Invitrogen Life Technologies, Carlsbad, CA, USA). 1 μg of
DNAse-treated RNA (RQ1 RNase-Free DNase kit, Pro-
mega, Madison, WI, USA) was retrotranscribed with High
Capacity cDNA Reverse Transcription Kit (Invitrogen Life
Technologies, Carlsbad, CA, USA). Quantitative PCR was
performed on an Applied Biosystems, 7900HT Fast Real-
Time PCR System (standard settings) using the Universal
Probe Library system (Roche Italia, Monza, Italy) and Pla-
tinum™ Quantitative PCR SuperMix-UDG (Invitrogen
Life Technologies, Carlsbad, CA, USA). Results were ana-
lyzed with the 2−ΔΔCt method using the 18S rRNA pre-
developed TaqMan assay (Invitrogen Life Technologies,
Carlsbad, CA, USA) as an internal control. The median
expression across samples was used as calibrator. The fol-
lowing primers and probes were used: Cox-2, forward:
GATGCTCTTCCGAGCTGTG reverse: GGATTGGAA-
CAGCAAGGATTT, probe number 45; E-cadherin:
forward: ATCCTCGCCCTGCTGATT and reverse:
ACCACCGTTCTCCTCCGTA, probe number 18.
Luciferase assay
To generate Cox-2 promoter luciferase reporter plas-
mids, two different Cox-2-promoter fragments were
generated by PCR, using A17 genomic DNA as tem-
plate, and the following primers: forward (-3195) 5’-
CGCGCTCGAGTTTTATTGTTCTGCCCTCATGTGT-
3’; forward (-965) 5’-CGCGCTCGAGCAACACAAACA-
CAGTAGGAAGATA-3’; reverse (+39) 5’-CGCGAA
GCTTGACTGACTCCTGAAGCTCTTAGCT-3’. The
fragments (-3195 bp/-965 bp to +39 bp), respectively
were cloned into pGL3-control vector expressing a fire-
fly luciferase (Promega, Madison, WI, USA) using XhoI
and HindIII restriction enzymes. The sequences of all
constructs were confirmed by sequencing (BMR Geno-
mics, Padova, Italy).
Luciferase activity was determined using a luciferase
assay system (Promega, Madison, WI, USA) according to
the manufacturer’s protocol. Briefly, silenced cells seeded
in 24-well plates (cells/well) were transiently transfected
with Cox-2-promoter luciferase reporter plasmids with
Lipofectamine 2000 (Invitrogen Life Technologies, Carls-
bad, CA, USA). Upon 65 hrs of doxycycline treatment,
luciferase assay was performed using the luciferase assay
system (Promega, Madison, WI, USA) in a Berthold
LB 953 luminometer. pGL3-control vector (Promega,
Madison, WI, USA), in which the luciferase expression is
driven by SV40 promoter, was used as positive control.
Luciferase activity was expressed as relative light units
per mg of cell proteins as determined by Bio-Rad Protein
Assay Dye Reagent (Bio-Rad, Hercules, CA, USA). Each
experiment was prepared in triplicate, and data are
expressed as means ± SEM. Statistical significance was
assessed using a Student’s t test.
Immunoblotting analysis
Protein extracts and western blots were performed as
described in [6]. For tumor protein extraction, tissues
were removed, frozen in liquid nitrogen, and homoge-
nized in lysis buffer. Densitometric analysis was per-
formed using the GS 250 Molecular Imager (Bio-Rad,
Hercules, CA, USA)
Cell adhesion assay in vitro
Adhesion assays were performed as described in [11] on
dishes coated with 10 microgram/ml Collagen I.
In vivo tumor growth
Fvb-Neu mice were challenged subcutaneously in the
left inguinal region with 105 A17 Ctr shRNA, A17
p130Cas shRNA or A17 Cox-2 shRNA cells. The inci-
dence and growth of tumors were evaluated twice
weekly by measuring with calipers for the two perpendi-
cular diameters. Mice water supplemented with doxycy-
cline (0.1 mg/mL) was protected from light and changed
every two to three days. The use of animals was in com-
pliance with the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of
Health and was approved by the Animal Care and Use
Committee of Camerino University
Whole mount analysis, histology, and
immunohistochemistry
Histology and immunohistochemistry preparations were
performed as previously described [27].
For immunohistochemistry, these sections were incu-
bated for 30 min with primary antibodies. After wash-
ing, they were overlaid with biotinylated goat anti-rat or
anti-rabbit immunoglobulin (Vector Laboratories, Bur-
lingame, CA, USA) for 30 min. Unbound antibodies
were removed, and the slides were incubated with avi-
din-biotin complex/alkaline phosphatase (Dako, Milan,
Italy).
In silico analysis
Publicly available microarray data from the Netherlands
Cancer Institute of 295 early-stage breast cancer biop-
sies (GSE2034) [28] and from the Koo Foundation Sun
Yat-Sen Cancer Center (KFSYSCC) of 327 breast cancer
tissues (GSE20685) [29] were used. Before analysis, the
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dataset was gene mean centered by subtracting the
mean value for each gene across all samples of the com-
pendium from all data points, so that in all cases expres-
sion values of each data point were reported as positive
or negative depending on whether it was higher or
lower than the mean value of that gene across the
samples.
Statistical analysis was performed using a log-rank
(Mantel-Cox) test.
Statistical analysis
The results are representative of at least three indepen-
dent experiments performed in triplicate and are
expressed as the means ± SEM. Statistical analysis of
the data was performed using a Student’s t test.
Results and discussion
p130Cas silencing causes loss of mesenchymal features of
breast cancer cells
To investigate the role of p130Cas in mesenchymal
breast cancer cells, we generated cells expressing doxycy-
cline-inducible control or p130Cas shRNA sequences [6],
resulting in p130Cas silencing of about 90% (Figure 1A).
Remarkably, upon four days of doxycycline treatment,
p130Cas silenced cells underwent a switch from an elon-
gated mesenchymal phenotype to a polygonal epithelial-
like shape (Figure 1B, panels a, b) that reverted upon re-
expression of p130Cas in silenced cells (Figure 1B, panel
c), indicating that p130Cas tuning can control mesenchy-
mal breast cancer cell plasticity.
p130Cas silenced cells revealed decreased expression of
the transcriptional factors Snail, Slug and Twist, and of
the mesenchymal marker Vimentin, whose levels were
restored by re-expression of p130Cas (Figure 1C), or by
washing out doxycycline from A17 culture medium (Fig-
ure S1 in Additional file 1). Snail, Slug and Twist are
known to repress E-cadherin expression during EMT
[20,30]. Quantitative real-time PCR experiments and
western blot analysis (Figure 1D) showed that E-cadherin
was induced both at mRNA and protein levels upon
p130Cas silencing. Consistently, when p130Cas was re-
expressed in silenced A17 cells, E-cadherin expression
was strongly downregulated, returning to control levels.
Immunofluorescence staining clearly showed that upon
p130Cas silencing E-cadherin expression becomes detect-
able in A17 cells with a strong plasma membrane stain-
ing (Figure 1E, panels b and c) that is totally missing in
control (panel a) and in p130Cas reconstituted cells
(panel d). Thus p130Cas can modulate expression of
mesenchymal/epithelial markers, resulting in a reversible
transition from mesenchymal to epithelial features.
p130Cas has been already shown to play a role in the
intrinsic plasticity that allows cells to switch from epithe-
lial to mesenchymal phenotype in pancreatic cancer cells
[31], while the second member of the Cas protein family
NEDD9 controls EMT in breast [32,33], and melanoma
[34] cancer cells. Remarkably, by mass spectrometry-
based profiling, p130Cas tyrosine phosphorylation has
been described to be elevated in basal breast cancer cells
[35]. Genome-wide transcriptional profiling of a large set
of human breast cancer cell lines confirms that EMT fea-
tures are mostly associated with basal-like tumors
[36,37], suggesting a link between p130Cas expression
and basal breast tumors.
p130Cas-dependent Cox-2 expression is involved in
maintenance of mesenchymal phenotype
Cox-2 is frequently associated with aggressive breast can-
cer [38]. Cox-2 was found significantly overexpressed in
A17 cells, where it correlates with their mesenchymal sig-
nature [22,23]. Interestingly, in p130Cas silenced cells the
expression of Cox-2 markedly decreased, and was
restored by re-expressing p130Cas (Figure 2A, left panel).
qRT-PCR showed that in p130Cas silenced cells Cox-2
mRNA was reduced by 80% compared to control cells,
and restored to control levels after p130Cas re-expression
in silenced cells (Figure 2A, middle panel), suggesting
that p130Cas exerts a transcriptional control on Cox-2
expression. Luciferase assays on two DNA fragments cor-
responding to a short (-965, +39) and a long (-3195, +39)
Cox-2 promoter indicated that p130Cas silencing signifi-
cantly decreased Cox-2 promoter activity (Figure 2A,
right panel). Adhesion-dependent Cox-2 induction has
been previously described [39-41]. Consistently, plating
control and p130Cas silenced cells on Collagen I-coated
dishes for different times, showed that Cox-2 induction
both at mRNA and protein levels and was markedly
delayed and decreased in p130Cas silenced cells (Figure
2B). Taken together, these results show that p130Cas is a
key upstream element in the regulation of Cox-2 expres-
sion in breast cancer cells. As Cox-2 has been proposed
as a mediator of breast tumor epithelial-stroma interac-
tions, which promote growth and progression of in situ
tumors [42], these results suggest that p130Cas can
behave as a master regulator of tumor/microenvironment
interactions.
Interestingly, the p130Cas-dependent expression of Cox-
2 is instrumental for the regulation of breast cancer cells
plasticity. Indeed, re-expression of Cox-2 in p130Cas
silenced cells reverted cells to a mesenchymal morphology
(Figure 2C, panel c) and restored Snail, Slug and Twist
expression (Figure 2D). Accordingly, cells expressing dox-
ycycline-inducible Cox-2 shRNAs in which Cox-2 was
knocked down by about 90% (Figure 2E, right panels),
exhibited a clear switch from an elongated to a polygonal
epithelial shape (Figure 2E, panel b). Moreover, these cells
showed marked downregulation of Slug and Twist tran-
scriptional factors, while p130Cas expression was not
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Figure 1 p130Cas silencing promotes acquirement of epithelial traits in A17 cells. (A) Extracts from A17 cells expressing scramble (Ctr
shRNA) or p130Cas shRNAs (p130Cas shRNA) treated (days: 4) or not (days: 0) with doxycycline were blotted with antibodies to p130Cas. Actin
was used as loading control. (B) Representative images of one out of ten experiments performed in A17 cells as in (A) (a, b) and p130Cas
silenced cells reconstituted with human full-length (hFL) p130Cas (p130Cas shRNA + hFL p130Cas) (c) cultured in presence of doxycycline for
four days (20X magnification). Right panel: Quantification of length/width ratio on five distinct microscope fields in each condition (**P value
<0.001). (C) Extracts from cells as in (B) were probed with antibodies to p130Cas, Snail, Slug, Twist, Vimentin, and normalized with Vinculin. (D)
Left panels: quantification of E-cadherin mRNA by qRT-PCR in Control shRNA, p130Cas shRNA and in p130Cas silenced cells reconstituted with
human full-length p130Cas (hFLCas) A17 cells (**P <0.001). Right panel: cell extracts were blotted with antibodies to p130Cas, and E-cadherin.
Actin was used as loading control. (E) Representative images of E-cadherin immunofluorescence performed on cells as in (D) (100X
magnification).
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Figure 2 p130Cas-dependent Cox-2 transcriptional expression sustains mesenchymal features of A17 cells. (A) Left panels: extracts from
A17 cells expressing scramble (Ctr shRNA), p130Cas shRNAs (p130Cas shRNA) or reconstituted with human full-length (hFL) p130Cas (p130Cas
shRNA + hFL p130Cas) were blotted with antibodies to p130Cas and Cyclooxygenase-2 (Cox-2). Actin was used as loading control. Middle panel:
quantification of Cox-2 mRNA by qRT-PCR in cells as in (A) (**P <0.001). Right panel: luciferase activity assay in p130Cas silenced cells transfected
with pGL3 vectors carrying luciferase reporter gene downstream of a short (-965, +39) or long (-3195, +39) stretch of Cox-2 promoter in
presence or absence of doxycycline (*P <0.05 and **P <0.001). Negative control: pGL3 vector lacking promoter. Positive control: pGL3 vector, in
which the luciferase expression is driven by SV40 promoter. (B) Left panels: Ctr and p130Cas silenced A17 cells treated with doxycycline for four
days were plated on Collagen I-coated dishes for different times. Cell extracts were analyzed by blotting with antibodies to Cox-2. Actin was
used as loading control. Right panel: quantification of adhesion-dependent Cox-2 mRNA by qRT-PCR (*P <0.05 and **P <0.001). (C) Upper panels:
representative images of one out of three experiments performed in Ctr shRNA cells (a), p130Cas shRNA cells (b) or p130Cas shRNA cells
reconstituted with hFL Cox-2 (p130Cas shRNA + hFL Cox2) (c) cultured in presence of doxycycline for four days (20X magnification). Lower
panel: quantification of length/width ratio on five distinct microscope fields in each condition (**P <0.001). (D) Right panels: cell extracts were
probed with antibodies to Cox-2, Snail, Slug, and Twist. Actin was used as loading control. Left panels: quantification analysis and statistic were
performed on three independent experiments. (E) Left panels: representative images from A17 cells expressing scramble (Ctr shRNA) (a) or Cox-2
shRNAs (Cox-2 shRNA) (b) treated with doxycycline for four days (20X magnification). Right panels: extracts from Ctr or Cox-2 silenced A17 cells
were blotted with antibodies to Cox-2, Slug, Twist, and Actin, used as loading control.
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affected (Figure 2E, right panels). These results indicate
that p130Cas controls Cox-2 expression and that Cox-2 is
involved in p130Cas-dependent maintenance of mesench-
ymal phenotype, thus establishing a p130Cas/Cox-2 axis
that sustains the mesenchymal features of breast cancer
cells.
The p130Cas/Cox-2 axis controls in vivo tumor properties
of breast cancer cells
To investigate the role of p130Cas/Cox-2 axis on tumor
growth, syngeneic mice were subcutaneously injected
with 105 control or p130Cas silenced cells and treated
with doxycycline in drinking water. Within three weeks,
all the 31 mice injected with control cells gave rise to
tumors with a mean diameter of 8 mm. In contrast, 38%
(28 out of 73) of mice injected with p130Cas silenced
cells did not give rise to detectable tumors and the
remaining 45 mice developed small tumors, with a mean
diameter of 2 mm (Figure 3A, left panel). Interestingly,
p130Cas silencing was sufficient to halt tumor growth in
mice that have already developed tumors with a diameter
of 3 to 4 mm. Indeed, by adding doxycycline to drinking
water two weeks after cell injection, p130Cas silenced
tumors regressed, becoming undetectable by palpation
within two to three weeks, while control tumors contin-
ued to grow (Figure 3A, right panels). Consistently, after
doxycycline withdrawal p130Cas silenced tumors
resumed growing. These data strengthen the in vivo rele-
vance of p130Cas as a major regulator of the tumorigenic
properties of mesenchymal breast cancer cells. We have
previously shown that intranipple injection of p130Cas
siRNAs in the mammary gland of Balb/c-NeuT mice sig-
nificantly decreases the number of cancer lesions com-
pared to glands injected with control siRNAs [6], with a
significant downregulation of proliferative and survival
pathways. Overall these data indicate that tight modula-
tion of p130Cas levels can affect in vivo tumor properties
of distinct breast cancer subtypes, implying the compel-
ling need of studying its transcriptional regulation in nor-
mal mammary epithelial cells and in tumors in the near
future.
Hematoxylin and eosin staining of tumor sections
showed that tumors derived from p130Cas silenced cells
consisted of cells with an epithelial-like shape, while the
control tumors presented elongated, mesenchymal cells
(Figure 3B, panels a, b). Moreover, immunohistochemis-
try analysis indicated that tumors from p130Cas silenced
cells were characterized by decreased vascularization
and proliferation (CD31 and pCNA staining), and
increased apoptosis (de novo expression of Caspase-3)
(Figure 3B, panels c-h).
Western blot analysis of p130Cas silenced tumors
showed a significant in vivo p130Cas silencing together
with Cox-2 downregulation, compromised activation of
c-Src and JNK kinases and decreased expression of
Cyclin D1 (Figure 3C, left panels). A parallel downregu-
lation of Snail, Slug and Twist expression was also
detected (Figure 3C, right panels), indicating that
p130Cas silencing compromises tumor growth through
inhibition of cell signaling controlling cell cycle progres-
sion and the acquirement of epithelial-like features. In
parallel, syngeneic mice were subcutaneously injected
with 105 Cox-2 silenced or control A17 cells and treated
with doxycycline in drinking water. As shown in Figure
3D, while mice injected with control cells gave rise to
tumors with a mean diameter of 10 mm within six
weeks, mice injected with Cox-2 silenced cells give rise
to barely detectable tumors. Taken together these data
show that p130Cas/Cox2 axis controls in vivo survival
and proliferative pathways of mesenchymal breast can-
cer cells and silencing of either p130Cas or Cox-2 is suf-
ficient for switching cells to an epithelial state leading to
impaired tumor growth.
The p130Cas/Cox2 axis requires c-Src and JNK activities
to sustain mesenchymal traits
To assess whether the p130Cas/Cox-2 axis is effective
also in the human setting, we chose the human lung
metastatic MDA-MB-231 subpopulation LM2-4175
[25,26] as they recapitulate A17 cell features with high
levels of Cox-2 expression and a mesenchymal pheno-
type. Upon infection with lentiviral particles carrying
human p130Cas shRNA, the marked downregulation of
p130Cas was associated with a concomitant decrease in
Cox-2, Snail, Slug and Twist (Figure 4A, left panels).
Accordingly, p130Cas silenced cells reorganized in colo-
nies that lost their elongated protrusions, acquiring a
more polygonal shape (Figure 4A, panels b and e), as
quantified by a marked decreased in length/width ratio.
Re-expression of a mouse full-length p130Cas-GFP
fused protein (mFLCas) in LM2-4175 p130Cas silenced
cells, re-established Cox-2 and mesenchymal markers
expression at the same level of control cells (Figure 4A,
left panels), and consistently p130Cas reconstituted cells
reacquired elongated protrusions (Figure 4A, panels c
and f). Moreover, p130Cas silencing led to a strong
reduction of c-Src and JNK activities (Figure 4A, left
panels), similar to those observed in in vivo tumor grafts
derived from p130Cas silenced A17 cells. Interestingly,
cell treatment with specific inhibitors of c-Src (SU6656)
or JNK (SP600125) activities for 16 hrs, caused a switch
to an epithelial morphology similar to that observed
upon p130Cas downregulation (Figure 4B, left panels).
Consistent with the fact that Src and JNK controls Cox-
2 expression (for review, [43]), both inhibitors caused
downregulation of Cox-2, and a reduction in Snail, Slug
and Twist expression (Figure 4B, right panels), without
grossly affecting p130Cas levels. In addition, cells treated
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Figure 3 p130Cas/Cyclooxygenase-2 (Cox-2) modulates A17 in vivo growth. (A) Left panel: A17 cells expressing Ctr shRNA or p130Cas
shRNAs were orthotopically injected in FVB-NeuN mice. Doxycycline has been supplied in drinking water at the time of injection. Tumor mean
diameter at 21 days after injection is reported on the y-axis (**P <0.001). Right panel: cells were orthotopically injected in mice and allowed to
grow for two weeks giving rise to tumors with a mean diameter of 1 mm. Doxycycline was then added to water of mice to induce the
expression of Ctr or p130Cas shRNA and tumors diameter were measured every week for four weeks. Finally, at the beginning of the sixth week,
doxycycline was removed and tumor growth was measured for other six weeks. n/n: number of measured tumors/injected mice for each group.
(B) Representative images of hematoxylin and eosin staining and immunohystochemical analysis of Ctr or p130Cas silenced tumor sections. The
antibodies against CD31 (c, d), pCNA (e, f) and cleaved caspase-3 (g, h) were used on paraffin-embedded sections (4X magnification).
Quantification of immunohystochemical analysis was performed by counting CD31 positive vessels in eight different fields at 200X magnification,
by expressing pCNA percentage of positive nuclei on the total nuclei, and by counting cleaved caspase-3-positive cells of 20 fields at 400X
magnification. (C) Protein extracts from Ctr or p130Cas silenced tumors were blotted with antibodies to p130Cas, pSrc (pTyr416), c-Src, Cox-2,
Cyclin D1, pJnk (Thr183/Tyr185), Snail, Slug, Twist, and Vinculin as loading control. (D) A17 cells expressing Ctr shRNA or Cox-2 shRNAs were
orthotopically injected in FVB-NeuN mice. Doxycycline had been supplied in drinking water at the time of injection. Tumor mean diameter at
four weeks after injection is reported on the y-axis (**P <0.001). n: number of measured tumors for each group.
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Figure 4 p130Cas/Cyclooxygenase-2 (Cox-2) axis sustains mesenchymal traits and predicts poor outcome in human breast cancers. (A)
Left panels: extracts from LM2-4175 cells expressing scramble (Ctr shRNA), p130Cas shRNAs (p130Cas shRNA) or silenced p130Cas cells
reconstituted with mouse full-length GFP. p130Cas (mFLCas) were blotted with antibodies to p130Cas, Cox-2, Snail, Slug, Twist, pSrc (pTyr416),
pJnk (Thr183/Tyr185), and Vinculin as loading control. Right panels: representative images (10X magnification) of Ctr (a), p130Cas silenced (b),
and p130Cas reconstituted (c) LM2-4175 cells. A 20X magnification of the squared field is shown (d, e, and f). Quantification of length/width
ratio on five distinct microscope fields in each condition (**P <0.001) is shown. (B) Left panels: representative images of LM2-4175 cells treated
with DMSO (a), 10 micromolar c-Src inhibitor (SU6656) (b), or 40 micromolar JNK inhibitor (SP600125) (c) for 16 h. 20X magnification of the
squared field are shown below (d-f). Right panels: protein extracts were blotted with antibodies against p130Cas, Cox-2, pSrc (pTyr416), c-Src,
pJnk (Thr183/Tyr185), Snail, Slug, Twist, and Vinculin as loading control. (C) In silico analysis of NKI dataset. Before analysis, the dataset was gene
mean centered by subtracting the mean value for each gene across all samples of the compendium from all data points, so that in all cases
expression values of each data point were reported as positive or negative depending on whether it was higher or lower than the mean value
of that gene across the samples. Kaplan-Meier curves indicating survival probability of patients with tumors overexpressing p130Cas and Cox-2
(double positive), compared to tumors with an expression of p130Cas and Cox-2 lower than the mean value previously defined (non-double
positive). (D) In silico analysis as in (C) on the Koo Foundation Sun Yat-Sen Cancer Center dataset.
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with the c-Src inhibitor SU6656 showed a decrease in
JNK activity, while the JNK inhibitor SP600125 did not
affect c-Src phosphorylation, suggesting that Src activity
is upstream to JNK activation. Moreover, in A17 cells,
luciferase assays revealed that the reporter expression
driven by Cox-2 promoter was decreased by the use of
Src inhibitor and practically abrogated with JNK inhibi-
tor (Figure S2 in Additional file 1). Overall these data
show that the p130Cas/Cox-2 axis is effective both in
the mouse and in the human setting. c-Src and JNK
kinases appear as sequential players in this axis and
their pharmacological inhibition was sufficient to down-
regulate Cox-2 and to induce an epithelial phenotype.
These results also suggest the potential clinical applica-
tion of targeting c-Src through pharmacological inhibi-
tors in breast tumors expressing high levels of p130Cas
and Cox-2, the same strategy already proposed in
HER2-positive trastuzumab-resistant tumors to over-
come trastuzumab resistance [44].
Finally, in order to evaluate whether the p130Cas/Cox-
2 axis has clinical relevance in human breast cancer, pub-
licly available microarray data from the Netherlands Can-
cer Institute of 295 early-stage breast cancer biopsies [28]
and from the Koo Foundation Sun Yat-Sen Cancer Cen-
ter (KFSYSCC) of 327 breast cancer tissues [29] were
analyzed. Kaplan-Meier curves showed that p130Cas and
Cox-2 double positivity was associated with the lowest
time survival (log-rank Van de Vijver P = 0.0025 and Kao
P = 0.0071) (Figure 4C, D), and the highest frequency of
recurrence (log-rank P = 0.0013) (Figure 4C), indicating
that high levels of p130Cas/Cox-2 co-expression relates
to the worst prognosis in breast cancer. Previous data
have already shown that high levels of p130Cas correlate
with intrinsic resistance to tamoxifen treatment in a large
subset of estrogen receptor (ER)-positive human breast
tumors (reviewed in [3]). Moreover, in human breast
cancers overexpression of both HER2 and p130Cas is
associated with poor prognosis [10].
Conclusions
Overall in this work we demonstrate the involvement of
p130Cas in mesenchymal breast cancer cell plasticity,
highlighting a new pathway linking p130Cas to Cox-2
through c-Src and JNK activities (Figure 5). p130Cas is
thus emerging as a critical player for onset and progres-
sion of many aggressive cancers, strengthening its rele-
vance as an unfavorable prognostic marker and a
putative therapeutic target, mostly in combination with
high levels of ER, HER2 or Cox-2, respectively.
Additional material
Additional file 1: Supplementary Figures. Figure S1. p130Cas
expression controls mesenchymal/epithelial behavior of A17 cells.
Morphological shape and biochemical analysis of A17 cells expressing
scramble or p130Cas shRNAs upon doxycycline treatment or doxycycline
wash-out. Figure S2. c-Src and JNK regulate the reporter expression
Figure 5 Schematic model illustrating the role of p130Cas in sustaining the mesenchymal features of breast cancer cells. p130Cas
supports mesenchymal traits of breast cancer cells by sustaining Src, JNK activities (see stars), and expression of Cyclooxygenase-2 (Cox-2),
leading to tumor growth. In contrast, low levels of p130Cas, preventing the activation of downstream signaling pathways, allow cells to acquire
epithelial features, impairing tumor growth.
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driven by Cyclooxygenase-2 (Cox-2) promoter. Luciferase activity
assay in A17 cells upon pharmacological treatments with Src or JNK
inhibitors.
Abbreviations
Cox-2: Cyclooxygenase-2; DMEM: Dulbecco’s modified Eagle’s medium; EMT:
epithelial-mesenchymal transition; ER: estrogen receptor; FCS: fetal calf
serum; GFP: green fluorescent protein; mAb: monoclonal antibody; MET:
mesenchymal epithelial transition; qRT-PCR: quantitative real-time
polymerase chain reaction; shRNA: short hairpin RNA; siRNA: small interfering
RNA.
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